BIO 2017: Panellists talk Amgen Sandoz biosimilar battle


Earlier this month, the US Supreme Court handed down its decision in the biosimilars battle between Amgen and Sandoz, centring on the Biologics Price Competition and Innovation Act (BPCIA).

BIO 2017, Amgen, Sandoz, biosimilars, patent dance, biologics, FDA, BPCIA, US Supreme Court